Products for Research Use Only
RegisterLogin

Bortezomib-d8

CAT: 0804-HY-10227S-01Size: 100 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10227S-01Size:100 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) [1][2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) [7].
Product Name Alternative
PS-341-d8; LDP-341-d8; NSC 681239-d8
UNSPSC
12352005
Target
Apoptosis; Autophagy; Isotope-Labeled Compounds; NF-κB; Proteasome; TREM receptor
Type
Isotope-Labeled Compounds
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Others
Field of Research
Cancer
Purity
98.0
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic) |Ethanol : 66.67mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OB([C@H](CC(C)C)NC(C(NC(C1=NC=CN=C1)=O)([2H])C([2H])([2H])C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])=O)O
Molecular Formula
C19H17D8BN4O4
Molecular Weight
392.29
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59 (11) :2615-22.|[3]Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1 (7) :913-24.|[4]Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107 (1) :257-64.|[5]Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3 (2) :333-9.|[6]Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12 (67) :471-80.|[7]Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281 (2) :1107-18.|[8]Wang Y, et al. TREM2-Mediated Cholesterol Efflux in Macrophages Inhibits Anti-Tumor Immunity via Limitation of CD4+ T and NK Cells. Adv Sci (Weinh) . 2025 Oct 20:e06995.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-10227-01Bortezomib
HY-10227R-01Bortezomib (Standard)
HY-W048404-01Bortezomib impurity A
HY-10227GBortezomib (GMP)
HY-169144Bortezomib analog
HY-125939-01Bortezomib-pinanediol
HY-135396-01(1S,2S) -Bortezomib
HY-Z4561S-01Bortezomib trimer-d15
HY-W048407Bortezomib impurity 12
HY-169158Bortezomib analog 1

Alternative Products

CatalogName
TRC-B675702-10MGBortezomib-D8 (Major)
TRC-H818157-50MG(1S)-3-Hydroxy Bortezomib-d8
412802-01(1S) -3-Hydroxy Bortezomib-d8 discontinued
RM-B201439-01Bortezomib

Popular Products